top of page

Pipeline
Who We Are
NanO₂
Glioblastoma
Publications
News
Contact
More

Use tab to navigate through the menu items.

The latest from NuvOx

All Posts
News
Events
Publications
Hemorrhagic Shock
Mechanism Of Action
Myocardial Infarction
Oncology
Pharmacokinetics
Stroke
Traumatic Brain Injury
Other

Search

NuvOx to Participate in the BIO CEO Investor Conference

Tucson, AZ, February 10, 2022 – NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat...

Feb 9, 2022

NuvOx to Present at Various Bio Forums in JPM Week Tucson, AZ, January 7, 2022

Tucson, AZ, January 7, 2022 – NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat...

Jan 12, 2022

Evan Unger for MedInvest Oncology Investor Conference November 2021

Evan Unger for MedInvest Oncology Investor Conference November 2021

Evan Unger for MedInvest Oncology Investor Conference November 2021

Nov 30, 2021

NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in Stroke

Tucson, AZ, October 12, 2021 --(PR.com)-- NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small...

Oct 15, 2021

NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts Efficacy of Immunotherapy

Tucson, AZ, September 09, 2021 --(PR.com)-- NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive...

Sep 9, 2021

NuvOx Therapeutics

1635 E 18th Street

Tucson, Arizona 85719

Terms & Conditions

© 2025 NuvOx Therapeutics

Pipeline
Who We Are
NanO₂
Glioblastoma

Publications
News
Contact
Careers

bottom of page